Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Proof-of-Concept in Psoriatic Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Vimirogant (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Proof of concept
- Sponsors Allergan; Vitae Pharmaceuticals
- 05 Nov 2018 New trial record